An Experimental Drug’s Bitter End – NYTimes.com

By ANDREW POLLACK Holly Usrey-Roos will never forget when her son, Parker, then 10, accidentally broke a drinking glass and said, “I’m sorry, Mom. I love you.” Ms. Usrey-Roos with her son, Parker. The experimental drug he took for years, she said, “opened the lid and let Parker out.” Now, however, the drug is being taken away. The situation raises questions about what, if anything, drug companies owe to patients participating in their clinical trials. It also points out the difficulties in developing drugs to treat autism and fragile X syndrome. If the drug worked so well in some patients, why has it not succeeded so far in clinical trials? Read the article:  An Experimental Drug’s Bitter End – NYTimes.com.

Read more

Seaside Therapeutics Ends Fragile X Clinical Trials

Seaside Therapeutics Ends Fragile X Clinical Trials

Seaside reports that their arbaclofen trial in adolescents and adults did not succeed. Today Seaside Therapeutics announced: “We regret to inform you that Study 209FX303 [An Open-Label Extension Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of STX209 (arbaclofen) in Subjects with Fragile X Syndrome] is being terminated immediately. The closure of the study is due to resource limitations at Seaside Therapeutics, Inc., and is not related to any known safety issue in patients dosed with STX209.” Seaside Therapeutics has indicated that this was a decision motivated primarily by financial constraints. However, since we first posted this update (on May 15), Seaside has also reported that their trial of arbaclofen in adolescents and adults with Fragile X did not succeed. [toggle_box] [toggle_item title=”More Information for Families” active=”false”] We are very sorry for all the families who are suffering this loss! Here are a few notes we’ve put together which we

Read more